25 XP   0   0   10

Esperion Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Esperion together

PenkeI guess you are interested in Esperion Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Esperion Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Esperion Therapeutics Inc

I send you an email if I find something interesting about Esperion Therapeutics Inc.

Quick analysis of Esperion (30 sec.)










What can you expect buying and holding a share of Esperion? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-2.46
Expected worth in 1 year
$-3.17
How sure are you?
15.0%

+ What do you gain per year?

Total Gains per Share
$-0.71
Return On Investment
-36.6%

For what price can you sell your share?

Current Price per Share
$1.94
Expected price per share
$1.82 - $3.4
How sure are you?
50%

1. Valuation of Esperion (5 min.)




Live pricePrice per Share (EOD)

$1.94

Intrinsic Value Per Share

$-10.01 - $8.06

Total Value Per Share

$-12.47 - $5.61

2. Growth of Esperion (5 min.)




Is Esperion growing?

Current yearPrevious yearGrowGrow %
How rich?-$454.9m-$289.6m-$102m-26.0%

How much money is Esperion making?

Current yearPrevious yearGrowGrow %
Making money-$59.1m-$71.9m$12.7m21.6%
Net Profit Margin-214.1%-381.4%--

How much money comes from the company's main activities?

3. Financial Health of Esperion (5 min.)




What can you expect buying and holding a share of Esperion? (5 min.)

Welcome investor! Esperion's management wants to use your money to grow the business. In return you get a share of Esperion.

What can you expect buying and holding a share of Esperion?

First you should know what it really means to hold a share of Esperion. And how you can make/lose money.

Speculation

The Price per Share of Esperion is $1.935. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Esperion.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Esperion, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-2.46. Based on the TTM, the Book Value Change Per Share is $-0.18 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.17 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Esperion.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.30-15.7%-0.28-14.6%-0.32-16.3%-0.26-13.3%-0.20-10.5%
Usd Book Value Change Per Share-0.24-12.6%-0.18-9.2%-0.17-8.9%-0.14-7.5%-0.07-3.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.24-12.6%-0.18-9.2%-0.17-8.9%-0.14-7.5%-0.07-3.7%
Usd Price Per Share2.99-1.74-5.98-21.31-29.87-
Price to Earnings Ratio-2.46--1.51--4.76--9.62--48.55-
Price-to-Total Gains Ratio-12.30--18.29--149.77--72.27--190.53-
Price to Book Ratio-1.22--0.81--3.81-70.61-56.69-
Price-to-Total Gains Ratio-12.30--18.29--149.77--72.27--190.53-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.935
Number of shares516
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.18-0.14
Usd Total Gains Per Share-0.18-0.14
Gains per Quarter (516 shares)-91.47-74.47
Gains per Year (516 shares)-365.88-297.86
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-366-3760-298-308
20-732-7420-596-606
30-1098-11080-894-904
40-1464-14740-1191-1202
50-1829-18400-1489-1500
60-2195-22060-1787-1798
70-2561-25720-2085-2096
80-2927-29380-2383-2394
90-3293-33040-2681-2692
100-3659-36700-2979-2990

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%2.038.00.05.0%2.061.01.03.1%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%6.034.00.015.0%12.049.03.018.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.064.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%6.034.00.015.0%12.049.03.018.8%

Fundamentals of Esperion

About Esperion Therapeutics Inc

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Fundamental data was last updated by Penke on 2024-04-11 07:07:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Esperion Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Esperion earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Esperion to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -174.7% means that $-1.75 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Esperion Therapeutics Inc:

  • The MRQ is -174.7%. The company is making a huge loss. -2
  • The TTM is -214.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-174.7%TTM-214.1%+39.4%
TTM-214.1%YOY-381.4%+167.2%
TTM-214.1%5Y-1,539.0%+1,324.9%
5Y-1,539.0%10Y-770.3%-768.7%
1.1.2. Return on Assets

Shows how efficient Esperion is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Esperion to the Drug Manufacturers - Specialty & Generic industry mean.
  • -27.4% Return on Assets means that Esperion generated $-0.27 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Esperion Therapeutics Inc:

  • The MRQ is -27.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -25.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.4%TTM-25.7%-1.7%
TTM-25.7%YOY-24.1%-1.6%
TTM-25.7%5Y-20.1%-5.6%
5Y-20.1%10Y-16.9%-3.2%
1.1.3. Return on Equity

Shows how efficient Esperion is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Esperion to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.0% Return on Equity means Esperion generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Esperion Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-60.5%+60.5%
5Y-60.5%10Y-38.8%-21.7%

1.2. Operating Efficiency of Esperion Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Esperion is operating .

  • Measures how much profit Esperion makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Esperion to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -131.4% means the company generated $-1.31  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Esperion Therapeutics Inc:

  • The MRQ is -131.4%. The company is operating very inefficient. -2
  • The TTM is -139.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-131.4%TTM-139.0%+7.7%
TTM-139.0%YOY-237.9%+98.8%
TTM-139.0%5Y-1,422.0%+1,283.0%
5Y-1,422.0%10Y-711.8%-710.2%
1.2.2. Operating Ratio

Measures how efficient Esperion is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 2.31 means that the operating costs are $2.31 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Esperion Therapeutics Inc:

  • The MRQ is 2.314. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.554. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.314TTM2.554-0.240
TTM2.554YOY3.379-0.825
TTM2.5545Y22.001-19.447
5Y22.00110Y11.009+10.992

1.3. Liquidity of Esperion Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Esperion is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.29 means the company has $1.29 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Esperion Therapeutics Inc:

  • The MRQ is 1.287. The company is just able to pay all its short-term debts.
  • The TTM is 1.916. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.287TTM1.916-0.629
TTM1.916YOY3.149-1.234
TTM1.9165Y3.164-1.248
5Y3.16410Y10.231-7.067
1.3.2. Quick Ratio

Measures if Esperion is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Esperion to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.84 means the company can pay off $0.84 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Esperion Therapeutics Inc:

  • The MRQ is 0.837. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.479. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ0.837TTM1.479-0.642
TTM1.479YOY2.939-1.460
TTM1.4795Y2.951-1.471
5Y2.95110Y13.693-10.742

1.4. Solvency of Esperion Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Esperion assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Esperion to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 3.21 means that Esperion assets are financed with 321.1% credit (debt) and the remaining percentage (100% - 321.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Esperion Therapeutics Inc:

  • The MRQ is 3.211. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 2.740. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ3.211TTM2.740+0.471
TTM2.740YOY1.983+0.757
TTM2.7405Y1.690+1.049
5Y1.69010Y0.900+0.790
1.4.2. Debt to Equity Ratio

Measures if Esperion is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Esperion to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Esperion Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y2.204-2.204
5Y2.20410Y1.174+1.031

2. Market Valuation of Esperion Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Esperion generates.

  • Above 15 is considered overpriced but always compare Esperion to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -2.46 means the investor is paying $-2.46 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Esperion Therapeutics Inc:

  • The EOD is -1.589. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.455. Based on the earnings, the company is expensive. -2
  • The TTM is -1.508. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.589MRQ-2.455+0.866
MRQ-2.455TTM-1.508-0.947
TTM-1.508YOY-4.760+3.251
TTM-1.5085Y-9.617+8.109
5Y-9.61710Y-48.550+38.933
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Esperion Therapeutics Inc:

  • The EOD is -2.416. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.733. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.508. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.416MRQ-3.733+1.317
MRQ-3.733TTM-2.508-1.225
TTM-2.508YOY-6.338+3.830
TTM-2.5085Y-11.221+8.713
5Y-11.22110Y-65.869+54.648
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Esperion is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Esperion Therapeutics Inc:

  • The EOD is -0.787. Based on the equity, the company is expensive. -2
  • The MRQ is -1.216. Based on the equity, the company is expensive. -2
  • The TTM is -0.811. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.787MRQ-1.216+0.429
MRQ-1.216TTM-0.811-0.405
TTM-0.811YOY-3.815+3.004
TTM-0.8115Y70.613-71.423
5Y70.61310Y56.691+13.922
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Esperion Therapeutics Inc.

3.1. Institutions holding Esperion Therapeutics Inc

Institutions are holding 41.691% of the shares of Esperion Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Wasatch Advisors Inc.4.80460.14648891103-2634997-22.8611
2023-12-31Two Seas Capital LP4.15355.61167686120139500.1818
2023-12-31Vanguard Group Inc2.77640.000351377503963888.3602
2023-12-31Bellevue Group AG2.27190.1923420426400
2023-12-31Meditor Group Ltd2.048814.1668379130000
2023-12-31Millennium Management LLC1.8640.00453449451-2344578-40.4654
2023-12-31Armistice Capital, LLC1.72920.1306320000032000000
2023-09-30Point72 Asset Management, L.P.1.6740.00893097852-1877148-37.7316
2023-12-31Junked Platinum Investment Management Ltd1.51880.34122810555-378962-11.8815
2023-12-31Two Sigma Investments LLC1.26150.016233441087647560.1176
2023-09-30Jacobs Levy Equity Management, Inc.1.22360.013122643591836567429.3131
2023-12-31Two Sigma Advisers, LLC1.160.015214660061030039.7253
2023-12-31Goldman Sachs Group Inc1.14280.0006211480293780679.6779
2023-12-31BlackRock Inc1.14180.000221128991450207.3694
2023-12-31JPMorgan Chase & Co1.00650.00051862470-1862-0.0999
2023-09-30TANG CAPITAL MANAGEMENT LLC0.99970.2558185000000
2023-12-31Parkman Healthcare Partners LLC0.77020.60021425204-571867-28.6353
2023-12-31Renaissance Technologies Corp0.76740.006614201001213944588.8473
2023-12-31Susquehanna International Group, LLP0.75130.00081390274792434132.5495
2023-09-30Schonfeld Strategic Advisors LLC0.66570.00941231827-84273-6.4032
Total 33.731721.520862421340+2129197+3.4%

3.2. Funds holding Esperion Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.89430.0009535593400
2023-12-31Wasatch Ultra Growth2.52991.1686468169900
2023-09-30BB Biotech AG Ord2.26640.1699419406400
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.86250.00391596028467303.0162
2023-12-31Wasatch Micro Cap0.8080.7104149519600
2024-02-29Fidelity Extended Market Index0.37940.004670213612628821.9308
2024-02-29JPMorgan US Small Company L0.33520.158762034400
2023-12-31Vanguard Explorer Inv0.24090.006244579800
2023-12-31Renaissance Global Small Cap0.21810.258440355500
2024-03-31BlackRock Extended Equity Market K0.19560.006736190012438452.3687
2023-12-31Vanguard VIF Small Co Gr0.15290.055928290500
2023-09-30BlackRock Extended Mkt Composite0.14710.001927225010887066.6361
2023-12-31Wasatch Long/Short Alpha Institutional0.10751.28881989375521138.4141
2024-03-28iShares Micro-Cap ETF0.10460.056419350400
2024-02-29Fidelity Total Market Index0.10130.000518742300
2023-12-31Wasatch Global Opportunities Investor0.0790.202914616100
2024-02-29VY® JPMorgan Small Cap Core Equity S0.07720.0807142946-3513-2.3986
2024-02-29Fidelity Series Total Market Index0.07630.0005141227-2938-2.0379
2023-12-31Jacob Discovery Fd Instl0.07031.92171300001300000
2023-12-31LVIP JPMorgan Small Cap Core Standard0.06480.198311985343593.7742
Total 11.71136.295921671860+589391+2.7%

3.3. Insider Transactions

Insiders are holding 0.803% of the shares of Esperion Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-20Eric WarrenSELL7421.25
2023-08-18Eric WarrenSELL2431.41
2023-07-19Eric WarrenSELL1061.58
2023-06-21Eric WarrenSELL6031.48
2023-05-17Eric WarrenSELL2191.62
2023-05-10J Martin CarrollBUY84091.49
2023-05-09Sheldon L KoenigBUY200001.26
2023-04-19Benjamin LookerSELL12901.27
2023-04-19Eric WarrenSELL1151.28

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Esperion Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.243-0.177-27%-0.171-30%-0.144-41%-0.071-71%
Book Value Per Share---2.459-2.116-14%-1.565-36%-0.950-61%0.067-3782%
Current Ratio--1.2871.916-33%3.149-59%3.164-59%10.231-87%
Debt To Asset Ratio--3.2112.740+17%1.983+62%1.690+90%0.900+257%
Debt To Equity Ratio----0%-0%2.204-100%1.174-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.304-0.283-7%-0.316+4%-0.257-15%-0.203-33%
Free Cash Flow Per Share---0.200-0.183-9%-0.236+18%-0.201+0%-0.154-23%
Free Cash Flow To Equity Per Share---0.176-0.115-35%-0.192+9%-0.015-92%0.001-21153%
Gross Profit Margin--1.0001.0000%1.041-4%1.018-2%1.009-1%
Intrinsic Value_10Y_max--8.065--------
Intrinsic Value_10Y_min---10.009--------
Intrinsic Value_1Y_max---0.412--------
Intrinsic Value_1Y_min---1.035--------
Intrinsic Value_3Y_max---0.308--------
Intrinsic Value_3Y_min---3.101--------
Intrinsic Value_5Y_max--0.917--------
Intrinsic Value_5Y_min---5.141--------
Market Cap358077539.520-55%553308446.080321529573.600+72%1107079524.640-50%3942553994.560-86%5527394081.296-90%
Net Profit Margin---1.747-2.141+23%-3.814+118%-15.390+781%-7.703+341%
Operating Margin---1.314-1.390+6%-2.379+81%-14.220+982%-7.118+442%
Operating Ratio--2.3142.554-9%3.379-32%22.001-89%11.009-79%
Pb Ratio-0.787+35%-1.216-0.811-33%-3.815+214%70.613-102%56.691-102%
Pe Ratio-1.589+35%-2.455-1.508-39%-4.760+94%-9.617+292%-48.550+1878%
Price Per Share1.935-55%2.9901.738+72%5.983-50%21.305-86%29.869-90%
Price To Free Cash Flow Ratio-2.416+35%-3.733-2.508-33%-6.338+70%-11.221+201%-65.869+1665%
Price To Total Gains Ratio-7.959+35%-12.298-18.286+49%-149.774+1118%-72.274+488%-190.526+1449%
Quick Ratio--0.8371.479-43%2.939-72%2.951-72%13.693-94%
Return On Assets---0.274-0.257-6%-0.241-12%-0.201-27%-0.169-38%
Return On Equity----0%-0%-0.6050%-0.3880%
Total Gains Per Share---0.243-0.177-27%-0.171-30%-0.144-41%-0.071-71%
Usd Book Value---454994000.000-391659750.000-14%-289654000.000-36%-175886650.000-61%12358750.000-3782%
Usd Book Value Change Per Share---0.243-0.177-27%-0.171-30%-0.144-41%-0.071-71%
Usd Book Value Per Share---2.459-2.116-14%-1.565-36%-0.950-61%0.067-3782%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.304-0.283-7%-0.316+4%-0.257-15%-0.203-33%
Usd Free Cash Flow---37056000.000-33871750.000-9%-43706750.000+18%-37198150.000+0%-28581325.000-23%
Usd Free Cash Flow Per Share---0.200-0.183-9%-0.236+18%-0.201+0%-0.154-23%
Usd Free Cash Flow To Equity Per Share---0.176-0.115-35%-0.192+9%-0.015-92%0.001-21153%
Usd Market Cap358077539.520-55%553308446.080321529573.600+72%1107079524.640-50%3942553994.560-86%5527394081.296-90%
Usd Price Per Share1.935-55%2.9901.738+72%5.983-50%21.305-86%29.869-90%
Usd Profit---56344000.000-59187250.000+5%-71954250.000+28%-51719500.000-8%-39108125.000-31%
Usd Revenue--32250000.00029083500.000+11%18868750.000+71%32308350.0000%20766025.000+55%
Usd Total Gains Per Share---0.243-0.177-27%-0.171-30%-0.144-41%-0.071-71%
 EOD+2 -6MRQTTM+12 -19YOY+14 -185Y+10 -2310Y+8 -25

4.2. Fundamental Score

Let's check the fundamental score of Esperion Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.589
Price to Book Ratio (EOD)Between0-1-0.787
Net Profit Margin (MRQ)Greater than0-1.747
Operating Margin (MRQ)Greater than0-1.314
Quick Ratio (MRQ)Greater than10.837
Current Ratio (MRQ)Greater than11.287
Debt to Asset Ratio (MRQ)Less than13.211
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.274
Total2/10 (20.0%)

4.3. Technical Score

Let's check the technical score of Esperion Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.455
Ma 20Greater thanMa 502.560
Ma 50Greater thanMa 1002.504
Ma 100Greater thanMa 2002.280
OpenGreater thanClose2.120
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets205,796
Total Liabilities660,790
Total Stockholder Equity-454,994
 As reported
Total Liabilities 660,790
Total Stockholder Equity+ -454,994
Total Assets = 205,796

Assets

Total Assets205,796
Total Current Assets201,065
Long-term Assets4,731
Total Current Assets
Cash And Cash Equivalents 82,248
Net Receivables 48,494
Inventory 65,623
Other Current Assets 4,700
Total Current Assets  (as reported)201,065
Total Current Assets  (calculated)201,065
+/-0
Long-term Assets
Property Plant Equipment 4,675
Other Assets 0
Long-term Assets  (as reported)4,731
Long-term Assets  (calculated)4,675
+/- 56

Liabilities & Shareholders' Equity

Total Current Liabilities156,224
Long-term Liabilities504,566
Total Stockholder Equity-454,994
Total Current Liabilities
Short-term Debt 36,381
Accounts payable 31,718
Other Current Liabilities 62,723
Total Current Liabilities  (as reported)156,224
Total Current Liabilities  (calculated)130,822
+/- 25,402
Long-term Liabilities
Long term Debt 261,596
Capital Lease Obligations 4,573
Long-term Liabilities Other 239,950
Long-term Liabilities  (as reported)504,566
Long-term Liabilities  (calculated)506,119
+/- 1,553
Total Stockholder Equity
Common Stock118
Retained Earnings -1,549,284
Other Stockholders Equity 1,094,172
Total Stockholder Equity (as reported)-454,994
Total Stockholder Equity (calculated)-454,994
+/-0
Other
Capital Stock118
Cash and Short Term Investments 82,248
Common Stock Shares Outstanding 112,403
Current Deferred Revenue25,402
Liabilities and Stockholders Equity 205,796
Net Debt 458,699
Net Invested Capital -193,398
Net Working Capital 44,841
Property Plant and Equipment Gross 6,687
Short Long Term Debt Total 540,947



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-31
> Total Assets 
30,489
25,877
82,872
77,877
72,396
68,280
84,963
78,340
72,220
64,305
57,087
51,407
44,272
38,153
99,430
2,180
0
0
0
7,312
22,265
19,534
86,576
78,294
70,223
69,287
60,530
143,344
325,221
315,958
306,394
295,572
286,036
277,466
263,791
245,213
214,612
185,242
313,093
277,835
244,188
210,881
174,030
143,451
236,482
308,814
255,270
214,447
179,642
330,352
250,969
353,258
278,606
280,461
225,256
381,590
342,853
303,980
312,827
247,939
251,819
234,626
221,305
205,796
205,796221,305234,626251,819247,939312,827303,980342,853381,590225,256280,461278,606353,258250,969330,352179,642214,447255,270308,814236,482143,451174,030210,881244,188277,835313,093185,242214,612245,213263,791277,466286,036295,572306,394315,958325,221143,34460,53069,28770,22378,29486,57619,53422,2657,3120002,18099,43038,15344,27251,40757,08764,30572,22078,34084,96368,28072,39677,87782,87225,87730,489
   > Total Current Assets 
28,107
23,084
76,404
71,340
65,487
61,477
77,825
71,286
64,833
57,342
50,499
45,263
38,448
32,603
93,818
0
0
0
0
7,138
22,123
19,389
72,964
60,620
58,279
61,319
54,579
106,767
279,826
225,713
218,845
214,394
197,054
209,088
213,467
213,577
188,013
170,948
206,823
203,924
201,408
188,883
168,210
142,632
235,221
307,121
253,460
211,714
172,629
321,371
242,803
345,896
272,575
275,174
170,668
328,972
290,819
252,478
261,785
246,683
250,605
232,125
218,227
201,065
201,065218,227232,125250,605246,683261,785252,478290,819328,972170,668275,174272,575345,896242,803321,371172,629211,714253,460307,121235,221142,632168,210188,883201,408203,924206,823170,948188,013213,577213,467209,088197,054214,394218,845225,713279,826106,76754,57961,31958,27960,62072,96419,38922,1237,138000093,81832,60338,44845,26350,49957,34264,83371,28677,82561,47765,48771,34076,40423,08428,107
       Cash And Cash Equivalents 
27,698
22,685
75,638
70,228
64,661
53,687
76,985
70,286
63,923
45,678
41,386
40,499
31,605
28,206
64,685
1,571
0
0
0
6,512
20,886
16,627
71,896
56,537
48,638
47,944
40,232
85,038
208,641
129,787
80,824
77,336
37,207
48,768
47,140
38,165
19,867
20,373
21,024
34,468
30,823
24,380
26,755
36,973
174,836
274,344
211,978
166,130
149,386
298,489
215,748
304,962
217,939
219,186
103,672
208,892
150,364
122,940
159,399
124,775
144,911
138,470
114,833
82,248
82,248114,833138,470144,911124,775159,399122,940150,364208,892103,672219,186217,939304,962215,748298,489149,386166,130211,978274,344174,83636,97326,75524,38030,82334,46821,02420,37319,86738,16547,14048,76837,20777,33680,824129,787208,64185,03840,23247,94448,63856,53771,89616,62720,8866,5120001,57164,68528,20631,60540,49941,38645,67863,92370,28676,98553,68764,66170,22875,63822,68527,698
       Short-term Investments 
0
0
0
0
0
7,034
0
0
0
11,084
8,360
4,354
6,253
4,019
27,707
0
0
0
0
0
0
0
0
3,525
8,064
11,780
12,729
20,803
69,467
94,995
134,772
134,925
157,263
158,410
162,961
173,418
162,017
147,035
182,347
165,731
166,400
155,793
132,463
99,050
53,692
26,882
31,883
34,651
7,931
2,247
0
0
0
0
0
50,441
68,138
62,905
29,942
42,086
17,427
0
0
0
00017,42742,08629,94262,90568,13850,441000002,2477,93134,65131,88326,88253,69299,050132,463155,793166,400165,731182,347147,035162,017173,418162,961158,410157,263134,925134,77294,99569,46720,80312,72911,7808,0643,5250000000027,7074,0196,2534,3548,36011,0840007,03400000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22,255
21,854
21,710
22,934
25,116
27,844
31,489
33,729
36,415
40,799
42,623
48,494
48,49442,62340,79936,41533,72931,48927,84425,11622,93421,71021,85422,2550000000000000000000000000000000000000000000000000000
       Other Current Assets 
409
399
766
1,112
826
756
840
1,000
910
580
753
410
590
378
1,426
293
0
0
0
627
1,237
2,762
1,068
557
1,577
1,595
1,618
926
1,718
931
3,249
2,133
2,584
1,910
3,366
1,994
6,129
3,540
3,452
3,725
4,185
8,710
8,992
6,609
185
198
260
10,933
13,471
12,387
17,994
24,798
34,606
10,420
11,314
12,311
11,547
9,557
11,410
9,866
5,584
4,317
6,287
4,700
4,7006,2874,3175,5849,86611,4109,55711,54712,31111,31410,42034,60624,79817,99412,38713,47110,9332601981856,6098,9928,7104,1853,7253,4523,5406,1291,9943,3661,9102,5842,1333,2499311,7189261,6181,5951,5775571,0682,7621,2376270002931,4263785904107535809101,0008407568261,112766399409
   > Long-term Assets 
2,381
2,793
6,468
6,537
6,909
6,803
7,138
7,054
7,387
6,963
6,588
6,144
5,824
5,550
5,612
0
0
0
0
174
142
145
13,612
17,674
11,944
7,968
5,951
36,577
45,395
90,245
87,549
81,178
88,982
68,378
50,324
31,636
26,599
14,294
106,270
73,911
42,780
21,998
5,820
819
1,261
1,693
1,810
2,733
7,013
8,981
8,166
7,362
6,031
5,287
54,588
52,618
52,034
51,502
51,042
1,256
1,214
2,501
3,078
4,731
4,7313,0782,5011,2141,25651,04251,50252,03452,61854,5885,2876,0317,3628,1668,9817,0132,7331,8101,6931,2618195,82021,99842,78073,911106,27014,29426,59931,63650,32468,37888,98281,17887,54990,24545,39536,5775,9517,96811,94417,67413,61214514217400005,6125,5505,8246,1446,5886,9637,3877,0547,1386,8036,9096,5376,4682,7932,381
       Property Plant Equipment 
1,925
2,138
2,222
2,503
2,620
3,242
3,400
3,313
4,228
3,809
3,436
3,001
2,710
2,432
2,498
252
0
0
0
120
88
89
79
81
360
851
840
780
728
680
722
807
743
685
622
674
623
558
497
435
374
311
583
520
1,205
1,637
1,754
2,677
6,957
7,687
8,110
7,306
5,975
5,231
4,532
2,562
1,978
1,446
986
1,200
1,158
2,445
3,022
4,675
4,6753,0222,4451,1581,2009861,4461,9782,5624,5325,2315,9757,3068,1107,6876,9572,6771,7541,6371,205520583311374435497558623674622685743807722680728780840851360817989881200002522,4982,4322,7103,0013,4363,8094,2283,3133,4003,2422,6202,5032,2222,1381,925
       Goodwill 
0
0
0
0
0
0
0
3,108
0
0
0
3,108
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000003,1080003,1080000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,477
17,538
11,528
7,061
5,055
35,741
44,611
89,509
86,771
80,315
88,183
67,637
49,646
30,906
25,920
13,680
105,717
73,420
42,350
21,631
5,181
243
0
0
0
0
0
0
0
0
0
0
0
50,441
0
62,905
0
42,086
0
0
0
0
000042,086062,905050,441000000000002435,18121,63142,35073,420105,71713,68025,92030,90649,64667,63788,18380,31586,77189,50944,61135,7415,0557,06111,52817,53813,4770000000000000000000000
       Intangible Assets 
0
0
3,687
3,500
3,737
3,527
3,317
0
3,108
3,108
3,108
0
3,108
3,108
3,108
54
0
0
0
54
54
56
56
56
56
56
56
56
56
56
56
56
56
56
56
56
56
56
56
56
56
56
56
56
56
56
56
56
56
0
0
56
56
56
56
56
56
56
56
56
56
56
56
0
056565656565656565656565600565656565656565656565656565656565656565656565656565656565454000543,1083,1083,10803,1083,1083,10803,3173,5273,7373,5003,68700
       Long-term Assets Other 
456
655
559
534
552
34
421
633
51
46
44
35
6
10
6
0
0
0
0
0
0
0
0
0
0
0
0
-20,803
0
0
0
-134,925
0
0
0
-173,418
0
0
0
-165,731
0
0
0
-99,050
766
734
796
-34,651
5,510
1,294
56
6,030
56
56
50,000
50,000
50,000
-12,905
50,000
-42,086
-1,214
-2,501
0
0
00-2,501-1,214-42,08650,000-12,90550,00050,00050,00056566,030561,2945,510-34,651796734766-99,050000-165,731000-173,418000-134,925000-20,80300000000000061063544465163342134552534559655456
> Total Liabilities 
5,404
7,345
10,020
10,186
9,972
11,879
12,206
11,842
12,789
12,535
12,026
12,664
12,679
14,480
14,372
8,237
0
0
0
24,702
2,521
6,644
3,343
4,202
3,188
10,378
10,307
9,790
10,794
10,502
9,912
8,313
8,276
9,506
9,611
16,611
22,190
31,135
34,997
33,144
30,048
34,964
42,285
64,333
61,472
179,480
186,758
194,497
229,888
244,863
242,009
449,392
548,000
584,771
587,961
578,534
591,893
595,678
606,927
571,717
581,482
606,604
631,309
660,790
660,790631,309606,604581,482571,717606,927595,678591,893578,534587,961584,771548,000449,392242,009244,863229,888194,497186,758179,48061,47264,33342,28534,96430,04833,14434,99731,13522,19016,6119,6119,5068,2768,3139,91210,50210,7949,79010,30710,3783,1884,2023,3436,6442,52124,7020008,23714,37214,48012,67912,66412,02612,53512,78911,84212,20611,8799,97210,18610,0207,3455,404
   > Total Current Liabilities 
3,280
5,370
7,537
7,159
6,665
6,750
6,820
6,360
5,868
5,098
4,805
4,933
4,958
6,532
6,298
1,339
0
0
0
17,173
2,521
6,644
3,343
4,202
3,188
5,456
5,631
5,491
6,939
7,029
6,828
5,625
5,993
7,635
8,160
15,589
21,605
30,995
34,997
33,144
30,048
34,964
42,285
64,333
60,025
54,312
57,518
66,080
73,453
83,881
75,947
94,069
97,893
82,644
78,485
73,352
79,085
82,275
82,345
92,308
95,486
107,173
137,708
156,224
156,224137,708107,17395,48692,30882,34582,27579,08573,35278,48582,64497,89394,06975,94783,88173,45366,08057,51854,31260,02564,33342,28534,96430,04833,14434,99730,99521,60515,5898,1607,6355,9935,6256,8287,0296,9395,4915,6315,4563,1884,2023,3436,6442,52117,1730001,3396,2986,5324,9584,9334,8055,0985,8686,3606,8206,7506,6657,1597,5375,3703,280
       Short-term Debt 
495
495
495
697
697
1,076
952
863
1,067
955
975
1,061
1,081
1,102
1,052
0
0
0
0
15,241
0
0
0
0
0
0
253
638
1,030
1,427
1,578
1,604
1,629
1,656
1,682
1,709
1,737
1,764
1,479
1,045
603
152
0
0
184
199
267
454
1,913
2,232
2,631
2,587
2,340
2,346
2,402
1,392
1,217
957
693
384
305
687
918
36,381
36,3819186873053846939571,2171,3922,4022,3462,3402,5872,6312,2321,913454267199184001526031,0451,4791,7641,7371,7091,6821,6561,6291,6041,5781,4271,03063825300000015,24100001,0521,1021,0811,0619759551,0678639521,076697697495495495
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
638
0
0
0
1,604
0
1,656
1,682
1,709
1,737
1,904
1,479
1,045
603
152
0
0
184
0
0
5,236
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000005,23600184001526031,0451,4791,9041,7371,7091,6821,65601,604000638000000000000000000000000000
       Accounts payable 
1,038
1,143
2,642
3,936
2,525
1,409
2,621
2,925
2,969
2,282
1,489
1,687
1,878
1,389
1,110
691
0
0
0
476
927
1,656
1,945
2,232
2,098
4,211
3,299
2,040
2,899
3,305
1,979
707
1,540
1,566
1,783
4,595
11,636
18,714
19,503
20,375
11,962
22,482
18,630
44,893
33,270
28,404
23,735
28,856
15,114
29,690
17,584
51,975
30,342
29,353
20,745
17,559
26,829
12,832
18,580
23,040
17,065
24,558
26,214
31,718
31,71826,21424,55817,06523,04018,58012,83226,82917,55920,74529,35330,34251,97517,58429,69015,11428,85623,73528,40433,27044,89318,63022,48211,96220,37519,50318,71411,6364,5951,7831,5661,5407071,9793,3052,8992,0403,2994,2112,0982,2321,9451,6569274760006911,1101,3891,8781,6871,4892,2822,9692,9252,6211,4092,5253,9362,6421,1431,038
       Other Current Liabilities 
1,746
3,732
4,400
2,526
3,443
4,265
3,247
2,572
1,832
1,861
2,341
2,185
1,999
4,041
4,136
648
0
0
0
265
1,594
4,989
1,398
1,971
1,090
1,245
2,079
2,706
3,010
2,297
3,271
3,277
2,824
4,413
4,695
9,245
8,232
10,517
14,015
11,686
17,483
12,330
23,655
19,440
22,645
22,110
30,898
34,618
55,256
50,825
54,070
37,845
62,668
47,015
52,270
48,718
47,244
63,458
59,027
65,377
65,959
66,294
90,853
62,723
62,72390,85366,29465,95965,37759,02763,45847,24448,71852,27047,01562,66837,84554,07050,82555,25634,61830,89822,11022,64519,44023,65512,33017,48311,68614,01510,5178,2329,2454,6954,4132,8243,2773,2712,2973,0102,7062,0791,2451,0901,9711,3984,9891,5942650006484,1364,0411,9992,1852,3411,8611,8322,5723,2474,2653,4432,5264,4003,7321,746
   > Long-term Liabilities 
2,123
1,975
2,483
3,027
3,307
5,129
5,386
5,482
6,921
7,437
7,221
7,731
7,721
7,948
8,074
0
0
0
0
7,529
0
0
0
0
0
4,922
4,676
4,299
3,855
3,473
3,084
2,688
2,283
1,871
1,451
1,022
585
140
0
0
0
0
0
0
1,447
125,168
129,240
128,417
156,435
160,982
166,062
355,323
450,107
502,127
509,476
505,182
512,808
513,403
524,582
479,409
485,996
499,431
493,601
504,566
504,566493,601499,431485,996479,409524,582513,403512,808505,182509,476502,127450,107355,323166,062160,982156,435128,417129,240125,1681,4470000001405851,0221,4511,8712,2832,6883,0843,4733,8554,2994,6764,922000007,52900008,0747,9487,7217,7317,2217,4376,9215,4825,3865,1293,3073,0272,4831,9752,123
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,922
4,676
4,299
3,855
3,473
3,084
2,688
2,283
1,871
1,451
1,022
585
140
0
0
0
0
0
0
0
0
0
0
0
0
0
179,367
271,694
272,098
272,508
0
258,678
259,080
259,487
0
260,316
260,738
0
0
00260,738260,3160259,487259,080258,6780272,508272,098271,694179,36700000000000001405851,0221,4511,8712,2832,6883,0843,4733,8554,2994,6764,9220000000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
65,228
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000065,228000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,898
0
0
0
2,529
2,529
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
655
124,409
128,420
0
0
0
1,710
1,290
1,290
2,347
2,135
634
422
211
0
0
0
0
0
0
0000002114226342,1352,3471,2901,2901,710000128,420124,409655000000000000000000000002,5292,5290001,898000000000000000
> Total Stockholder Equity
25,085
18,532
72,852
67,691
62,424
56,401
72,757
66,498
59,431
51,770
45,061
38,743
31,593
23,673
85,058
0
0
0
0
-17,390
19,744
12,890
83,233
74,091
67,035
58,909
50,223
133,554
314,427
305,456
296,482
287,259
277,760
267,960
254,180
228,602
192,422
154,107
278,096
244,691
214,140
175,917
131,745
79,118
175,010
129,334
68,512
19,950
-50,246
85,489
8,960
-838,817
-269,394
-304,310
-362,705
-196,944
-249,040
-1,229,432
-294,100
-1,340,036
-1,401,755
-371,978
-410,004
-454,994
-454,994-410,004-371,978-1,401,755-1,340,036-294,100-1,229,432-249,040-196,944-362,705-304,310-269,394-838,8178,96085,489-50,24619,95068,512129,334175,01079,118131,745175,917214,140244,691278,096154,107192,422228,602254,180267,960277,760287,259296,482305,456314,427133,55450,22358,90967,03574,09183,23312,89019,744-17,390000085,05823,67331,59338,74345,06151,77059,43166,49872,75756,40162,42467,69172,85218,53225,085
   Common Stock
2
2
26
26
26
26
29
29
29
29
29
29
29
29
34
0
0
0
0
0
10
0
15
15
15
15
15
20
22
22
23
23
23
23
23
23
23
23
26
26
27
27
27
27
27
27
27
27
28
28
28
26
26
26
27
61
61
65
72
75
87
101
112
118
118112101877572656161272626262828282727272727272727262623232323232323232222201515151515010000003429292929292929292626262622
   Retained Earnings -1,549,284-1,492,940-1,451,690-1,401,755-1,340,036-1,284,549-1,229,432-1,163,108-1,106,377-1,041,258-971,872-928,204-838,817-734,341-648,904-773,515-695,266-633,320-564,943-510,722-598,101-538,062-488,151-442,421-396,291-358,400-313,181-269,844-229,200-200,244-182,842-168,807-154,222-141,100-128,299-115,904-104,438-94,981-85,175-75,937-68,063-58,374-53,135-46,323-41,9750000-116,450-109,887-101,452-94,046-87,427-80,447-72,623-65,320-58,976-52,695-46,370-40,389-34,824-24,020-17,506
   Accumulated Other Comprehensive Income 
-626
-799
-988
-1,256
-1,256
-1,256
-1,256
-2,415
-2,415
-2,415
-2,415
-3,690
-3,690
-3,690
-3,690
0
0
0
0
-1,166
-1,198
0
6
-3
3
5
2
-59
-39
-60
11
-482
15
118
22
-172
-228
-239
-351
-845
-963
-776
-560
-319
-111
-16
11
23
9
0
0
-1,571
0
0
0
-31
-263
-297
-93
-2
-1
0
0
0
000-1-2-93-297-263-31000-1,5710092311-16-111-319-560-776-963-845-351-239-228-1722211815-48211-60-39-59253-360-1,198-1,1660000-3,690-3,690-3,690-3,690-2,415-2,415-2,415-2,415-1,256-1,256-1,256-1,256-988-799-626
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
797
141,585
142,142
142,954
144,064
145,187
238,031
430,348
433,793
437,548
441,940
446,529
450,661
454,379
457,951
462,471
467,504
636,821
641,801
657,497
664,817
670,340
677,511
685,816
694,266
701,794
715,166
723,232
734,365
743,273
797,655
713,782
722,534
733,524
964,401
969,268
992,964
1,045,468
1,071,183
1,127,004
1,134,609
0
0
001,134,6091,127,0041,071,1831,045,468992,964969,268964,401733,524722,534713,782797,655743,273734,365723,232715,166701,794694,266685,816677,511670,340664,817657,497641,801636,821467,504462,471457,951454,379450,661446,529441,940437,548433,793430,348238,031145,187144,064142,954142,142141,585797000000000000000000000
   Treasury Stock00-54,998-54,998-54,998-54,998-54,998-54,998-54,998-54,998-54,998-54,998-54,998000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
43,215
43,349
108,638
109,310
110,024
110,326
132,960
134,204
134,440
134,603
134,874
136,450
136,706
137,221
205,164
0
0
0
0
1,776
67,255
797
-86,434,227
-78,151,718
142,954
144,064
145,187
238,031
430,348
433,793
437,548
441,940
446,529
450,661
454,379
457,951
462,471
467,504
636,821
641,801
657,497
664,817
670,340
677,511
685,816
694,266
701,794
715,166
723,232
734,365
743,273
-26
658,784
667,536
678,526
909,403
914,270
232
990,470
-73
-86
1,079,611
1,082,824
1,094,172
1,094,1721,082,8241,079,611-86-73990,470232914,270909,403678,526667,536658,784-26743,273734,365723,232715,166701,794694,266685,816677,511670,340664,817657,497641,801636,821467,504462,471457,951454,379450,661446,529441,940437,548433,793430,348238,031145,187144,064142,954-78,151,718-86,434,22779767,2551,7760000205,164137,221136,706136,450134,874134,603134,440134,204132,960110,326110,024109,310108,63843,34943,215



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue116,334
Cost of Revenue-43,431
Gross Profit72,90372,903
 
Operating Income (+$)
Gross Profit72,903
Operating Expense-228,466
Operating Income-155,563-155,563
 
Operating Expense (+$)
Research Development86,107
Selling General Administrative121,238
Selling And Marketing Expenses0
Operating Expense228,466207,345
 
Net Interest Income (+$)
Interest Income0
Interest Expense-58,976
Other Finance Cost-728
Net Interest Income-58,248
 
Pretax Income (+$)
Operating Income-155,563
Net Interest Income-58,248
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-209,248-101,878
EBIT - interestExpense = -214,539
-209,248
-150,272
Interest Expense58,976
Earnings Before Interest and Taxes (EBIT)-155,563-150,272
Earnings Before Interest and Taxes (EBITDA)-155,399
 
After tax Income (+$)
Income Before Tax-209,248
Tax Provision-0
Net Income From Continuing Ops-208,391-209,248
Net Income-209,248
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses271,897
Total Other Income/Expenses Net-53,68558,248
 

Technical Analysis of Esperion
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Esperion. The general trend of Esperion is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Esperion's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Esperion Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.97 < 3.4 < 3.4.

The bearish price targets are: 1.99 > 1.92 > 1.82.

Tweet this
Esperion Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Esperion Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Esperion Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Esperion Therapeutics Inc. The current macd is -0.01472696.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Esperion price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Esperion. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Esperion price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Esperion Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartEsperion Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Esperion Therapeutics Inc. The current adx is 28.65.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Esperion shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Esperion Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Esperion Therapeutics Inc. The current sar is 3.1948576.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Esperion Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Esperion Therapeutics Inc. The current rsi is 34.45. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Esperion Therapeutics Inc Daily Relative Strength Index (RSI) ChartEsperion Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Esperion Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Esperion price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Esperion Therapeutics Inc Daily Stochastic Oscillator ChartEsperion Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Esperion Therapeutics Inc. The current cci is -113.87982845.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Esperion Therapeutics Inc Daily Commodity Channel Index (CCI) ChartEsperion Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Esperion Therapeutics Inc. The current cmo is -45.89515756.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Esperion Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartEsperion Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Esperion Therapeutics Inc. The current willr is -99.65986395.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Esperion Therapeutics Inc Daily Williams %R ChartEsperion Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Esperion Therapeutics Inc.

Esperion Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Esperion Therapeutics Inc. The current atr is 0.3047941.

Esperion Therapeutics Inc Daily Average True Range (ATR) ChartEsperion Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Esperion Therapeutics Inc. The current obv is -15,415,978.

Esperion Therapeutics Inc Daily On-Balance Volume (OBV) ChartEsperion Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Esperion Therapeutics Inc. The current mfi is 61.66.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Esperion Therapeutics Inc Daily Money Flow Index (MFI) ChartEsperion Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Esperion Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Esperion Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Esperion Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.455
Ma 20Greater thanMa 502.560
Ma 50Greater thanMa 1002.504
Ma 100Greater thanMa 2002.280
OpenGreater thanClose2.120
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Esperion with someone you think should read this too:
  • Are you bullish or bearish on Esperion? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Esperion? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Esperion Therapeutics Inc

I send you an email if I find something interesting about Esperion Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Esperion Therapeutics Inc.

Receive notifications about Esperion Therapeutics Inc in your mailbox!